𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combining lectin affinity chromatography and immunodepletion – A novel method for the enrichment of disease-specific glycoproteins in human plasma

✍ Scribed by Naghmeh Mortezai; Christoph Wagener; Friedrich Buck

Book ID
116987369
Publisher
Elsevier Science
Year
2012
Tongue
English
Weight
466 KB
Volume
56
Category
Article
ISSN
1046-2023

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Preparation of a high-performance multi-
Preparation of a high-performance multi-lectin affinity chromatography (HP-M-LAC) adsorbent for the analysis of human plasma glycoproteins
✍ Majlinda Kullolli; William S. Hancock; Marina Hincapie 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 352 KB

## Abstract We report on the preparation of an improved multi‐lectin affinity support for HPLC separations. We combined the selectivity of three different lectins: concanavalin A (ConA), wheat germ agglutinin (WGA), and jacalin (JAC). Each lectin was first covalently immobilized onto a polymeric ma

A two step fractionation approach for pl
A two step fractionation approach for plasma proteomics using immunodepletion of abundant proteins and multi-lectin affinity chromatography: Application to the analysis of obesity, diabetes, and hypertension diseases
✍ M. K. Disni R. Dayarathna; William S. Hancock; Marina Hincapie 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 647 KB

## Abstract Plasma is an important biological material for biomarker discovery. However, the wide dynamic range in protein concentration remains a major challenge. In this paper, we introduce the development of a proteomic platform for analysis of plasma samples. The method utilizes a double fracti

Development and validation of a high-per
Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study
✍ Federica Sala; Elena Marangon; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maur 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

## Abstract CEP‐18770, [(1__R__)‐1‐{[(2__S__,3__R__)‐3‐hydroxy‐2‐{[(6‐phenyl‐2‐pyridinyl)carbonyl]amino}butanoyl]amino}‐3‐methylbutyl]boronic acid, is a novel proteasome inhibitor, now under early clinical evaluation as an anticancer agent. To investigate its clinical pharmacokinetics, a high‐perfo